Compare AMBO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | PPBT |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 6.5M |
| IPO Year | 2010 | N/A |
| Metric | AMBO | PPBT |
|---|---|---|
| Price | $2.91 | $0.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 691.0K |
| Earning Date | 08-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $9,699,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.29 | ★ N/A |
| Revenue Growth | ★ 23.73 | N/A |
| 52 Week Low | $1.59 | $0.53 |
| 52 Week High | $6.75 | $4.42 |
| Indicator | AMBO | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 45.71 |
| Support Level | $2.85 | $0.64 |
| Resistance Level | $3.27 | $0.72 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.55 | 60.63 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.